Phase II Trial of Infliximab for the Prevention of Acute Graft-Versus-Host Disease Following Allogenic Hematopoietic Stem Cell Transplantation.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Ciclosporin; Infliximab; Methotrexate
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 10 Jun 2015 Biomarkers information updated
- 25 Jan 2012 Actual patient number (24) and lead trial investigator (Hofmeister C) added as reported by ClinicalTrials.gov.
- 25 Jan 2012 Actual end date (March 2008) added as reported by ClinicalTrials.gov.